According to Tianyancha's business information, recently, Hualan Biological Vaccine Co., Ltd. underwent a commercial change. The registered capital was reduced from 601.027,500 yuan to 565.028 million yuan, a decrease of about 6%; at the same time, the legal representative was changed from An Kang to An Wenjue. Hualan Biological Vaccine Co., Ltd. was established in November 2005. The legal representative is An Wenjue, with a registered capital of 565.028 million yuan and a paid-in payment of 565.028 million yuan. Its business scope is to produce various vaccines and genetically engineered biological products and sell self-produced products. It is located at No. 1, Annex 1, Hualan Avenue, Xinxiang City, Henan Province. According to shareholder information, the company is controlled by Hualan Bioengineering Co., Ltd., and the securities used to be called “Hualan Biovaccine Co., Ltd.” This capital reduction coincided with pressure on the influenza vaccine industry: on the one hand, the company's share capital was reduced by about 36 million, and on the other hand, the former chairman An Wenjue was taken over by the second-generation “An” character — this is the first time since its establishment in 2005 that this domestic quadrivalent influenza vaccine manufacturer completed both “capital reduction+change of command” on the same day. The case is still being disclosed; in the end, the industrial and commercial registration shall prevail.

According to Tianyancha's business information, recently, Hualan Biological Vaccine Co., Ltd. underwent a commercial change. The registered capital was reduced from 601.027,500 yuan to 565.028 million yuan, a decrease of about 6%; at the same time, the legal representative was changed from An Kang to An Wenjue. Hualan Biological Vaccine Co., Ltd. was established in November 2005. The legal representative is An Wenjue, with a registered capital of 565.028 million yuan and a paid-in payment of 565.028 million yuan. Its business scope is to produce various vaccines and genetically engineered biological products and sell self-produced products. It is located at No. 1, Annex 1, Hualan Avenue, Xinxiang City, Henan Province. According to shareholder information, the company is controlled by Hualan Bioengineering Co., Ltd., and the securities used to be called “Hualan Biovaccine Co., Ltd.” This capital reduction coincided with pressure on the influenza vaccine industry: on the one hand, the company's share capital was reduced by about 36 million, and on the other hand, the former chairman An Wenjue was taken over by the second-generation “An” character — this is the first time since its establishment in 2005 that this domestic quadrivalent influenza vaccine manufacturer completed both “capital reduction+change of command” on the same day. The case is still being disclosed; in the end, the industrial and commercial registration shall prevail.